Manufacturing delays, financial barriers, and complex care coordination can limit access to gene therapy, emphasizing the need for patient-centered programs and long-term follow-up.
|Articles|November 15, 2018
- November 2018 Cough, Cold, & Flu
- Volume 84
- Issue 11
Pet Peeves (November 2018)
Read about this month's pet peeves.
Advertisement
CRANKSGIVING
Patients who are unusually rude when they come in during our Thanksgiving hours…trust me, I don’t want to be there any more than they do!
DRIVE-THRU MISUSE
When patients ask for items like candy and soda at the drive-thru.
SLOW-ACTING MEDICAL PRACTICE
Doctors who take hours to get back to us regarding a simple clarifying question.
GAME OF PHONES
When patients get angry at us over the phone because we put them on hold in order to help all of the patients who called before them.
Articles in this issue
almost 8 years ago
Estrogens and Lamotrigine: New Developmentsalmost 8 years ago
From Sea to Shining Sea Pertussis Outbreaks Across the Nationalmost 8 years ago
Iron Products Need Improved Labelingalmost 8 years ago
Florida Pharmacy Owner: "They Call Me First"almost 8 years ago
Chronic Cough: Differential Diagnosesalmost 8 years ago
Should We Believe Patients With Pain?almost 8 years ago
Understanding Naloxone Standing Orders Is VitalAdvertisement
Related to this article
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Experts highlighted how Diamond-Blackfan anemia illustrates the scientific, financial, and manufacturing challenges that can prevent promising gene therapies for ultra-rare diseases from reaching patients.
Experts highlighted recent gene therapy approvals for inherited immune disorders while addressing ongoing challenges in manufacturing, long-term safety, and patient access.
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
At the 2026 ASTCT Gene Therapy Summit, experts highlighted how chronic pain, psychological challenges, and neurologic complications may persist despite successful treatment.
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
ADA guidance ties monitoring choices to therapy, risk, and preference. Brooke Hudspeth, PharmD, explains how pharmacists help individualize the plan.
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Drives First-Line Immunotherapy Selection in NSCLC? Data, Payers, and Habit
2
Frontline Immunotherapy Options in NSCLC: Are Checkpoint Inhibitors Interchangeable?
3
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
4
October Neurology News: Huntington Disease Gene Therapy, Remibrutinib in MS, and AI Medical Advice
5